Recursion Pharmaceuticals (RXRX) News Today $7.14 -0.18 (-2.46%) (As of 03:15 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Pier 88 Investment Partners LLC Acquires 109,210 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Pier 88 Investment Partners LLC raised its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 442.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 133,910 shares of the company's stock after puNovember 14 at 7:00 AM | marketbeat.comRecursion and Exscientia Shareholders Approve the Proposed CombinationNovember 13 at 9:08 AM | globenewswire.comRecursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model GardenNovember 13 at 3:51 AM | markets.businessinsider.comLeerink Partnrs Has Bullish Outlook for RXRX FY2024 EarningsNovember 13 at 3:17 AM | americanbankingnews.comRecursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model GardenNovember 12 at 5:02 PM | globenewswire.comBaillie Gifford & Co. Cuts Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Baillie Gifford & Co. trimmed its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 5.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,239,870 shares of the company's stock afNovember 12 at 8:06 AM | marketbeat.comLeerink Partnrs Has Positive Outlook of RXRX FY2024 EarningsRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) - Analysts at Leerink Partnrs increased their FY2024 earnings estimates for shares of Recursion Pharmaceuticals in a research note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now forecasts that theNovember 11 at 1:51 AM | marketbeat.comAnalysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging HigherNovember 10, 2024 | finance.yahoo.comBalanced Hold Rating on Recursion Pharmaceuticals Amid Strategic Developments and Financial PerformanceNovember 10, 2024 | markets.businessinsider.comARK Investment Management LLC Has $215.95 Million Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)ARK Investment Management LLC lifted its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 16.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,769,186 shares of thNovember 8, 2024 | marketbeat.comRecursion Pharmaceuticals Reports Q3 2024 Earnings and Strategic MilestonesNovember 8, 2024 | markets.businessinsider.comBuy Rating for Recursion Pharmaceuticals Amid Strategic Merger and Innovative Drug DevelopmentNovember 8, 2024 | markets.businessinsider.comRecursion Pharmaceuticals (NASDAQ:RXRX) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday.November 7, 2024 | marketbeat.comRecursion Provides Business Updates and Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Hold Rating on Recursion Pharmaceuticals (RXRX)November 7, 2024 | markets.businessinsider.comRecursion Pharmaceuticals Inc (RXRX) Q3 2024 Earnings Report Preview: What To ExpectNovember 5, 2024 | finance.yahoo.comCathie Wood’s ARK Investment buys 106K shares of Recursion Pharmaceuticals todayNovember 5, 2024 | markets.businessinsider.comMirae Asset Global Investments Co. Ltd. Increases Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Mirae Asset Global Investments Co. Ltd. grew its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 1,173.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,539 shares oNovember 3, 2024 | marketbeat.comIs Recursion Pharmaceuticals a Millionaire-Maker Stock?November 2, 2024 | fool.comBlake Borgeson Sells 11,447 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) StockNovember 1, 2024 | insidertrades.comCathie Wood’s ARK Investment buys 729K shares of Recursion Pharmaceuticals todayNovember 1, 2024 | markets.businessinsider.comRecursion Pharmaceuticals (RXRX) to Release Earnings on WednesdayRecursion Pharmaceuticals (NASDAQ:RXRX) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports.October 31, 2024 | marketbeat.comRecursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6thOctober 30, 2024 | globenewswire.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 1.6% Following Insider SellingRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.6% Following Insider SellingOctober 29, 2024 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Sells $37,860.00 in StockOctober 29, 2024 | insidertrades.comTina Marriott Sells 6,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) StockRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) COO Tina Marriott sold 6,000 shares of the company's stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $6.31, for a total transaction of $37,860.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares of the company's stock, valued at $3,288,380.78. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.October 28, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 5.1% - Here's What HappenedRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 5.1% - Here's What HappenedOctober 28, 2024 | marketbeat.com3 Key Trends That Are Bullish for Recursion Pharmaceuticals StockOctober 26, 2024 | fool.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.8% Higher - Here's What HappenedRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.8% Higher - What's Next?October 25, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 0.2% - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 0.2% - Time to Sell?October 24, 2024 | marketbeat.comRecursion Pharmaceuticals call volume above normal and directionally bullishOctober 24, 2024 | markets.businessinsider.comRecursion Pharmaceuticals (RXRX): A Promising Small-Cap in Biotech InnovationOctober 23, 2024 | msn.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 0.9% - Should You Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 0.9% - Should You Sell?October 23, 2024 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Rating of "Hold" by BrokeragesRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) has received a consensus recommendation of "Hold" from the six analysts that are covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and two have given a buy recommendationOctober 23, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.5% - Here's What HappenedRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 1.5% - Here's WhyOctober 22, 2024 | marketbeat.comRecursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infectionOctober 22, 2024 | globenewswire.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.6% - Should You Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.6% - Should You Sell?October 21, 2024 | marketbeat.comState Street Corp's Strategic Acquisition in the Biotechnology SectorOctober 19, 2024 | finance.yahoo.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 2.9% - Still a Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 2.9% Higher - What's Next?October 18, 2024 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Sells $76,351.49 in StockOctober 18, 2024 | insidertrades.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 3.3% - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.3% - What's Next?October 17, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 1.9% - Still a Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 1.9% Higher - Here's WhyOctober 16, 2024 | marketbeat.comRecursion Pharmaceuticals (RXRX) Stock Moves -0.74%: What You Should KnowOctober 16, 2024 | msn.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 2.4% - Should You Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 2.4% - What's Next?October 15, 2024 | marketbeat.comCathie Wood Is Betting on This AI Stock: Is It a Buy?October 15, 2024 | fool.comDown 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?October 15, 2024 | fool.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 0.6% - Here's What HappenedRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 0.6% - Time to Sell?October 14, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 1% - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 1% - Here's What HappenedOctober 11, 2024 | marketbeat.comMichael Secora Sells 15,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) StockOctober 11, 2024 | insidertrades.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora Sells 15,000 SharesRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) CFO Michael Secora sold 15,000 shares of the stock in a transaction dated Tuesday, October 8th. The shares were sold at an average price of $6.32, for a total value of $94,800.00. Following the transaction, the chief financial officer now directly owns 1,426,506 shares in the company, valued at approximately $9,015,517.92. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.October 10, 2024 | marketbeat.com Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address 3 Dirt-Cheap Stocks You Can’t Afford to Ignore (Ad)Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances. Get your FREE look at these THREE companies right here. RXRX Media Mentions By Week RXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RXRX News Sentiment▼0.510.54▲Average Medical News Sentiment RXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RXRX Articles This Week▼187▲RXRX Articles Average Week Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SpringWorks Therapeutics News Today Arcus Biosciences News Today Schrödinger News Today AbCellera Biologics News Today Relay Therapeutics News Today Exscientia News Today Emergent BioSolutions News Today Absci News Today Viking Therapeutics News Today Elanco Animal Health News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RXRX) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
